BTIG Reiterates Buy on Monopar Therapeutics, Maintains $87 Price Target
Benzinga Newsdesk 1 year ago
NewsPrice TargetReiterationAnalyst Ratings
BTIG analyst Jeet Mukherjee reiterates Monopar Therapeutics (NASDAQ:MNPR) with a Buy and maintains $87 price target.
BTIG analyst Jeet Mukherjee reiterates Monopar Therapeutics (NASDAQ:MNPR) with a Buy and maintains $87 price target.